Preferences help
enabled [disable] Abstract
Number of results
2015 | 15 | 4 | 208–211
Article title

Zamiana apteczna leków przeciwpsychotycznych – perspektywa pacjentów leczonych z rozpoznaniem schizofrenii

Title variants
Languages of publication
Physical description
  • Araszkiewicz AA, Szabert K, Godman B et al.: Generic olanzapine: health authority opportunity or nightmare? Expert Rev Pharmacoecon Outcomes Res 2008; 8: 549–555.
  • Awad AG, Hogan TP: Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9: 585–588.
  • Awad AG, Voruganti LNP, Heslegrave RJ et al.: Assessment of the patient’s subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996; 11 Suppl 2: 55–59.
  • Bobo WV, Stovall JA, Knostman M et al.: Converting from brandname to generic clozapine: a review of effectiveness and tolerability data. Am J Health Syst Pharm 2010; 67: 27–37.
  • Desmarais JE, Beauclair L, Margolese HC: Switching from brandname to generic psychotropic medications: a literature review. CNS Neurosci Ther 2011; 17: 750–760.
  • Freudenreich O, Cather C, Evins AE et al.: Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 2004; 65: 1372–1376.
  • Hofer A, Kemmler G, Eder U et al.: Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002; 63: 49–53.
  • Hofer A, Rettenbacher MA, Edlinger M et al.: Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Acta Psychiatr Scand 2007; 116: 354–361.
  • Hogan TP, Awad AG, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13: 177–183.
  • Kesselheim AS, Misono AS, Shrank WH et al.: Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med 2013; 173: 202–208.
  • Murawiec S, Boutros NN: Correlation between early subjective response to antipsychotics and the number of hospitalizations and hospitalization days in a period of 10-11 years in schizophrenia patients. Neuropsychobiology 2012; 66: 120–125.
  • Murawiec S, Rajewska-Rager A, Samochowiec J et al.: Pharmacy switch of antipsychotic medications: patient’s perspective. Ann Gen Psychiatry 2015; 14: 31.
  • Oluboka O, Stewart S, Landry S et al.: Does therapeutic equivalence follow bioequivalence? A randomized trial to assess clinical effects after switching from Clozaril to generic clozapine (gen-clozapine). J Clin Pharmacol 2010; 50: 531–535.
  • Roman B: Patients’ attitudes towards generic substitution of oral atypical antipsychotics: a questionnaire-based survey in a hypothetical pharmacy setting. CNS Drugs 2009; 23: 693–701.
  • Sarwer-Foner GJ: The psychodynamic action of psychopharmacologic drugs and the target symptom versus the anti-psychotic approach to psychopharmacologic therapy: thirty years later. Psychiatr J Univ Ott 1989; 14: 268–278.
  • Van Putten T, May PRA, Marder SR et al.: Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187–190.
  • Van Putten T, May PRA: Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry 1978; 35: 477–480.
  • Voruganti L, Slomka P, Zabel P et al.: Subjective effects of AMPTinduced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D2 binding ratios on SPECT imaging. Neuropsychopharmacology 2001; 25: 642–650.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.